|
Home
CME Live Seminars
About the Program
Quick Order
Hotel Registration
Auto Rental
Accreditation
Cancellation Policy
Testimonials
CME Video DVD
CME Audio CD/MP3
Subscribe
Request Brochure
Hold Seat
Testing Online
Faculty
Resources
Contact Us
|
|
|
|
Live CME Seminars
Infectious Disease CME |
|
|
by Donald Kaye, M.D., M.A.C.P. - Drexel University, College of Medicine; Professor of Medicine, Philadelphia, PA; Elaine T. Kaye, M.D. - Harvard Medical School; Assistant Professor, Division of Dermatology; Attending Physician, Children's Hospital, Boston, MA; Keith S. Kaye, M.D., M.P.H. - Wayne State University School of Medicine; Professor of Medicine; Corporate Medical Director of Hospital Epidemiology and Antimicrobial Stewardship, Detroit Medical Center, Detroit, MI; Kenneth Kaye, M.D., F.A.C.P. - Harvard Medical School; Associate Professor of Medicine; Attending Physician, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA and Jerry Zuckerman, M.D. - Jefferson Medical College, Thomas Jefferson University; Assistant Professor of Medicine; Medical Director, Infection Prevention and Control, Division of Infectious Diseases, Albert Einstein Medical Center, Philadelphia, PA.
Learning Objectives
What do our past participants have to say?
Refer a Colleague to Our Website
|
|
Infectious Diseases in the Adult Patient: A Primary Care Update
December 28-31, 2009
Location: Hyatt Regency Sarasota, Florida
| SPECIFIC OBJECTIVES
| | Day 1 | Newer Antibacterial Agents - Upon completion of this session, using FDA publications and approvals as well as IDSA and SHEA evidence-based guidelines, the participant should be able to:
| 1. | Relate the antibacterial spectrum of activity.
| | 2. | Describe the pharmacology of the agents.
| | 3. | List the indications and dosing recommendations.
| | 4. | Identify the side effects, adverse reactions and drug interactions.
| | New or Emerging Infectious Diseases, Parts 1 & 2: Influenza; Clostridium difficile (CDI) - Upon completion of this session, according to SHEA and HICPAC position papers, and the CDC and WHO recommendations, the participant should be able to:
| | 1. | Explain the etiology and pathogenesis of these infections.
| | 2. | Describe the clinical approach and methods of diagnosing these infections.
| | 3. | Summarize the management of these infections including prevention.
| | Update on Antimicrobial Resistance - Upon completion of this session, the participant should be able to describe, using IDSA and SHEA evidence-based guidelines and CDC and WHO surveys:
| | 1. | The pattern of emergence of resistance of certain infecting bacteria.
| | 2. | The epidemiology that may indicate potential resistance among the organisms discussed, such as:
| a. | Pneumococci;
| | b. | Enterococci;
| | c. | Gram negative bacilli.
|
| | 3. | The approach to current therapeutic regimens while considering resistance.
| | Meningitis and Meningoencephalitis - Upon completion of this session, the participant should be able to use the evidence-based guidelines of the IDSA, and the CDC to:
| | 1. | Describe the epidemiology of meningitis and the different types of meningitis.
| | 2. | Identify clinical signs and symptoms of different types of meningitis.
| | 3. | Describe the indications for lumbar puncture (LP) and interpretations of LP results.
| | 4. | Summarize treatment options and the need for hospitalization and public health notification.
|
| | Day 2 | Adult immunizations, Part I - Upon completion of this session, the participant should be able to list the following, according to the IDSA, ACIP, CDC, and ACP evidence-based guidelines and recommendations:
| 1. | The adult immunization schedule.
| | 2. | Recommendations for timing and spacing of immunobiologics.
| | 3. | Indications, efficacy and current recommendations for the following vaccine preventable diseases: Influenza, pneumococcus and pertussis.
| | Methicillin Resistant Staphylococcus aureus (MRSA) - Using the evidence-based guidelines from the CDC, IDSA and SHEA, upon completion of this session, the participant should be able to describe:
| | 1. | The epidemiology of MRSA.
| | 2. | The important infections caused by MRSA.
| | 3. | The risk factors and outcomes associated with MRSA control and treatment of MRSA.
| | Adult Immunizations, Part II - Upon completion of this session, the participant should be able to list the indications, efficacy and current recommendations for the following vaccine preventable diseases according to the IDSA, ACIP, CDC, and ACP evidence-based guidelines and recommendations:
| |
| a. | Hepatitis A.
| | b. | Hepatitis B.
| | c. | Varicella-Zoster.
| | d. | Meningococcus.
| | e. | Human Papilloma Virus.
|
| | Cellulitis, Necrotizing Fasciitis and the Diabetic Foot Ulcers - Upon completion of this session, using the evidence-based guidelines from the IDSA, the participant should be able to:
| | 1. | Explain typical and atypical manifestations.
| | 2. | Discuss the pathogenesis.
| | 3. | List the principles of medical and surgical treatment.
| | 4. | Describe the prognosis.
| | Community Acquired Pneumonia - Upon completion of this session, the participant should be able to use the evidence based-guidelines of the IDSA and ATS to:
| | 1. | Identify the microbial causes of community acquired pneumonia.
| | 2. | Describe strategies utilized to triage patients to appropriate level of care.
| | 3. | Describe utility of current diagnostic tests.
| | 4. | Describe recommended treatment regimens.
|
| | Day 3 | Helicobacter pylori Infection - Upon completion of this session, using position statements from AGA, and evidence-based guidelines from ACOG, the participant should be able to:
| 1. | Describe the clinical manifestations of H. pylori infection.
| | 2. | Relate the methods of diagnosing H. pylori infection.
| | 3. | Summarize the treatment of H. pylori infection.
| | Tuberculosis - Using evidence-based guidelines and recommendations from ATS, IDSA, CDC, and WHO, upon completion of this session, the participant should be able to:
| | 1. | Identify groups at risk for developing active tuberculosis.
| | 2. | Describe the principles of antituberculous therapy.
| | 3. | Describe Mantoux technique for tuberculin skin testing.
| | 4. | Summarize indications for treatment of latent TB infection.
| | Hepatitis - Upon completion of this session, using evidence-based guidelines and consensus statements from NIH, CDC, AGA, ACIP, AAP and Association for the Study of Liver Disease, the participant should be able to:
| | 1. | Explain the pathogenesis and clinical manifestations of hepatitis A, B, C, D or E.
| | 2. | Discuss differences in rates of complications.
| | 3. | Summarize treatment options for hepatitis B and C and their rates of success.
| | HIV Primer for the Primary Care Physician - Using recommendations and evidence-based guidelines from IDSA, HIVMA, USPHS, CDC and ACP, upon completion of this session, the participant should be able to:
| | 1. | Discuss the latest epidemiology of HIV infection.
| | 2. | Describe recommendations for HIV screening.
| | 3. | Relate the utility of diagnostic tests (e.g. viral load, CD4 count) and their application for disease management.
| | 4. | Discuss the principles of antiretroviral treatment.
| | Herpesvirus Infections - Upon completion of this session, the participant should be able to, using the recommendations and evidence-based guidelines of ACIP, and AAP:
| | 1. | List the clinically pertinent aspects of herpesvirus infections.
| | 2. | Describe the syndromes, clinical complications and attributes of recurrent disease.
| | 3. | Relate the proper management and use of anti-virals.
| | Viruses to be covered include:
| |
| a. | Herpes simplex virus;
| | b. | Epstein-Barr virus;
| | c. | Cytomegalovirus;
| | d. | Varicella-zoster virus;
| | e. | HHV6.
|
|
| | Day 4 | Urinary Tract Infection - Upon completion of this session, using evidence-based guidelines of the IDSA, AUA and EBM publications, the participant should be able to:
| 1. | Relate the epidemiology of UTIs.
| | 2. | Distinguish the attributes of lower tract and upper tract infections and reinfections and relapses.
| | 3. | Identify chronic bacterial prostatitis.
| | 4. | Describe the approach to antimicrobial therapy, to include the use of short course therapy.
| | 5. | Summarize the approach to prevention.
| | Common Skin and Nail Infections - At the conclusion of this talk, using recommendations, statements, and guidelines from the CDC and BAD the participant should be able to describe the pathogenesis, differential diagnosis, and therapy for a variety of common cutaneous infections as follows:
| | 1. | Bacterial infections.
| | 2. | Fungal infections.
| | 3. | Viral infections.
| | 4. | Nail infections and other nail abnormalities.
| | 5. | Parasitic infestations.
| | Infective Diarrhea - Using IDSA, HICPAC, CDC, FDA, and WHO evidence-based guidelines and recommendations, upon completion of this session, the participant should be able to:
| | 1. | Differentiate the presentation of toxigenic and invasive diarrhea.
| | 2. | Identify food-borne pathogens.
| | 3. | Explain when to use fecal WBC, stool cultures, and stool O&P examinations.
| | 4. | Summarize the indications for antibiotic therapy.
| | 5. | Identify appropriate antibiotic choices.
| | Endocarditis Prophylaxis Guidelines: What the PCP Needs to Know - Upon completion of this session, based on evidence-based guidelines from the AHA, ADA, AAOS, and AUA the participant should be able to:
| | 1. | Discuss current recommendations for antibiotic prophylaxis of endocarditis and prosthetic joints.
| | 2. | Describe data supporting prophylaxis.
| | 3. | Identify appropriate patients for prophylaxis.
| | 4. | Summarize proper administration of prophylactic antibiotics.
| | 5. | Identify proper prophylaxis in the allergic patient.
| | Advice for the Traveler - Upon completion of this session, using recommendations from the CDC and evidence-based guidelines from IDSA, the participant should be able to:
| | 1. | Summarize the general preventive measures including what not to eat and drink.
| | 2. | List the needed immunizations.
| | 3. | Describe the prevention of malaria, diarrhea and other illnesses of travelers.
| | 4. | Relate the management of diarrhea of travelers.
|
|
|